Social Media Ideas for Adarx Pharmaceuticals

RNAi drug specialist ADARx raises $446M IPO

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare...

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow

An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide

Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

Axsome rises on Auvelity prescription data

Revolution Medicines

Revolution Medicines Anonymous (not verified) Wed, 09/30/2026 - 01:04 field_thread_url https://cafepharma.com/boards/threads/revolution-medicines.709803/...

ADVX Expands Medical Business Consulting Services in Melbourne

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

<![CDATA[FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer]]>

Primary Markets Group September 2026 U.S. IPO Update

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

FDA extends review of Capricor cell therapy; Pain drug startup to go public

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the pub...

Zydus, MSN Laboratories launch first generic Adempas in US

Zydus Lifesciences and MSN Laboratories have launched Riociguat tablets in the US after receiving approval from the USFDA

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health...

Corexa Health's three divisions - pharmacy, distribution, and tech & hub - positioned to serve the emerging compounded peptide market

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Breaking News: Daraxonrasib Approved for Pancreatic Cancer

Today, the U.S. Food and Drug Administration approved daraxonrasib (Rasonque), a groundbreaking new drug for pancreatic cancer that targets the RAS family of proteins. Catch up on...

<![CDATA[Roundup: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy, Enodia Therapeut...

ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer

FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common...

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcri...

DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on D...

Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and...

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13...